Feds adopt wait-and-see strategy for funding of therapeutic clinical trial of liberation therapy for multiple sclerosis

Kondro, Wayne
October 2010
CMAJ: Canadian Medical Association Journal;10/5/2010, Vol. 182 Issue 14, pE676
Academic Journal
The article reports on the wait-and-see strategic funding for the therapeutic clinical trial of the liberation therapy for multiple sclerosis (MS). It notes that the Canadian government will provide funding to Italian physician Paolo Zamboni on balloon venoplasty as a therapy for MS, given that Zamboni's propositions are valid. However, the blue-ribbon committee of the Canadian Institute of Health Research (CIHR) has rejected Zamboni's claims on his treatment procedure that used balloons.


Related Articles

  • The rise of people power. Chafe, Roger; Born, Karen B.; Slutsky, Arthur S.; Laupacis, Andreas // Nature;4/28/2011, Vol. 472 Issue 7344, p410 

    In this article, the authors discuss the impact of social media in research to improve treatment of multiple sclerosis (MS) in Canada. The authors mention the theory of Paolo Zamboni, a vascular surgeon from the University of Ferrara in Italy, on the new cause of MS which Zamboni called chronic...

  • Angioplasty Could Be a Future MS Treatment.  // Radiology Today;Apr2011, Vol. 12 Issue 4, p16 

    The article reports on the possibility that angioplasty might be a treatment for patients with multiple sclerosis (MS). It mentions that Italian physician Paolo Zamboni has published a study which shows that if angioplasty can widen blood vessels, then it could help lessen the severity of...

  • Streamline CRO Selection. Powers, Barbara // Applied Clinical Trials;Mar2001, Vol. 10 Issue 3, p50 

    Offers tips in selecting the right clinical research organization (CRO). Factors to consider when outsourcing specific studies; Identification of CRO who will get a request for proposal; Members of CRO selection team; Business risk assessment; Compliance level of CRO; Value of prequalification...

  • PAHPA Reauthorization Provides Certainty for MCMs. Serebrov, Mari // BioWorld Today;3/15/2013, Vol. 24 Issue 50, p1 

    The article discusses how the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) and a request for proposals (RFP) for 2.8 million courses of a granulocyte colony-stimulating factor (G-CSF) attest the U.S. government's commitment to funding medical countermeasures (MCM) to...

  • 80% Of Surveyed Companies Have Dedicated Investigator Initiated Trial Management Groups in Place, Finds Cutting Edge Information.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article provides information related to the survey on pharmaceutical companies dedicated to Investigator Initiated Trial (IIT) Management Groups in Place. It highlights that dedicated IIT groups also serve as the first line for proposal review, weeding out undesirable submissions and...

  • Promising results in early Antegren trial.  // Inside MS;Winter2002, Vol. 20 Issue 1, p36 

    Reports on the result of an early double-blind clinical trial of Antegren as announced at the 7th Congress of the European Committee on Treatment and Research in Multiple Sclerosis on September 15, 2001. Number of multiple sclerosis patients who participated in the trial; Effects of Antegren;...

  • One face behind the numbers. Yusuf, Katharine // American Journal of Health-System Pharmacy;11/1/2009, Vol. 66 Issue 21, p1955 

    A personal narrative is presented which explores the author's experience of participating in a clinical trial to cure her multiple sclerosis.

  • Focus on sex differences in grant applications submitted to the Netherlands Organization for Health Research and Development. Keuken, Debby G.; Haafkens, Joke A.; Klazinga, Niek S. // International Journal for Equity in Health;2007, Vol. 6, p13 

    Background: Several measures have been implemented at international level to ensure that there is a greater focus on sex differences in health research. This study evaluates the effect of various formal incentives that were introduced by a Dutch financer of health research to encourage...

  • "Media, politics and science policy: MS and evidence from the CCSVI Trenches". Pullman, Daryl; Zarzeczny, Amy; Picard, AndrĂ© // BMC Medical Ethics;2013, Vol. 14 Issue 1, p1 

    Background: In 2009, Dr. Paolo Zamboni proposed chronic cerebrospinal venous insufficiency (CCSVI) as a possible cause of multiple sclerosis (MS). Although his theory and the associated treatment ("liberation therapy") received little more than passing interest in the international scientific...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics